[FORM 10-K (Mark One) x December 31, 2015 For the fiscal year ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 86-29-33686638 (Former name, former] [Biostar Pharmaceuticals, Inc. List of subsidiaries As of December 31, 2015 Name Place of incorporation Shaanxi Biostar Biotech Ltd People’s Republic of China Shaanxi Aoxing Pharmaceutical Co. Ltd. People’s Republic of China Shaanxi Weinan Haren Pharmaceuticals, Ltd. People’s Republic of China EX-21 2 ex21.htm EX-21] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. Mazars CPA Limited Certified Public Accountants Hong Kong April 14, 2016 EX-23.1 3 ex23-1.htm EX-23.1] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. Mazars CPA Limited Certified Public Accountants Hong Kong April 14, 2016 EX-23.2 4 ex23-2.htm EX-23.2] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 dated July 17, 2014 of Biostar Pharmaceuticals, Inc. of our report dated April 14, 2016 relating to the consolidated financial statements, which appears in the Annual Report on Form] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this Annual 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION I, Qinghua Liu, certify that: 1. I have reviewed this Annual 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Dated: April 14, 2016 Ronghua Wang Chief Executive Officer EX-32.1 8 ex32-1.htm EX-32.1] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Dated: April 14, 2016 Qinghua Liu Interim Chief Financial Officer EX-32.2 9 ex32-2.htm EX-32.2]

[Biostar Pharmaceuticals Regains Compliance with NASDAQ $1.00 Minimum Bid Price XIANYANG, China, February 24, 2016 -- Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) (“Biostar”), a PRC-based developer, manufacturer and marketer of pharmaceutical and health supplement products in China, today announced that on February 22, 2016, NASDAQ notified the Company that it had regained compliance with continued listing Rule 5550(a)(2), which requires a] [FORM 8-K CURRENT REPORT Date of Report (Date of earliest event reported): February 24, 2016 BIOSTAR PHARMACEUTICALS, INC. Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) Identification No.) No. 588 Shiji Avenue, Xianyang City, Shaanxi Province, People’s Republic of China 712046 86-029-33686638 N/A (Former name or former address, if changed since last report) ¨ ¨ ¨]

[ARTICLES OF AMENDMENT TO THE ARTICLES OF INCORPORATION OF BIOSTAR PHARMACEUTICALS, INC. This is to certify that: FIRST SECOND THIRD FOURTH IN WITNESS WHEREOF Biostar Pharmaceuticals, Inc. Ronghua Wang Shuang Gong EX-3.1 2 ex3-1.htm EX-3.1] [Biostar Pharmaceuticals to Effect Reverse Stock Split XIANYANG, China, February 5, 2016 -- Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) (“Biostar” or “the Company”), a PRC-based developer, manufacturer and marketer of pharmaceutical and health supplement products in China, today announced that its Board of Directors unanimously approved a reverse split of its common stock at a ratio of 1-for-7, with anticipated trading] [FORM 8-K CURRENT REPORT Date of Report (Date of earliest event reported): February 4, 2016 BIOSTAR PHARMACEUTICALS, INC. Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) Identification No.) No. 588 Shiji Avenue, Xianyang City, Shaanxi Province, People’s Republic of China 712046 86-029-33686638 N/A (Former name or former address, if changed since last report) ¨ ¨ ¨]